Deadline Alert: Grail, Inc. (GRAL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Grail, Inc. (NASDAQ: GRAL) faces a class action securities fraud lawsuit after failing to meet the primary endpoint in its NHS-Galleri cancer trial on February 19, 2026. The announcement caused the stock to plummet 50.5%. Investors allege the company made materially false statements about trial results and failed to disclose that the three-year timeline was insufficient to demonstrate the primary endpoint, misleading shareholders about business prospects.